Phase II Study to Evaluate the Efficacy and Safety of GC6101A in Subjects With Gastritis

Inclusion Criteria: * Age is over 19 years old, men or women * Patients diagnosed with acute or chronic gastritis by gastroscopy * Patients with one or more erosions found by gastroscopy * Signed the informed consent forms Exclusion Criteria: * Patients who is impossible to receive gastroscopy * Patients with peptic ulcer and gastroesophageal reflux disease * Patients with gastroesophageal surgery and surgery to reduce the secretion of gastric acid (Except for surgery for perforated peptic ulcer and cecectomy) * Patients with esophageal varix * Patients with malignant neoplasm of gastrointestinal tract * Patients with thrombosis or administered with anti-thrombotic drugs * Patients with consumption coagulopathy * Patients administered with H2 receptor antagonists, muscarinic receptor antagonists, gastrin receptor antagonist, proton pump inhibitors, prostaglandins or mucosal protective agents prior to study in 2 weeks * Patient who cannot interrupt steroid, non-steroid anti-inflammatory drugs or aspirin during treatment * Allergic or hypersensitive to any of the ingredients in the test products * Pregnant or lactating female * Patients who have abnormal baseline laboratory test result * Patients taking other investigational drugs within 30 days prior to the study. * Patients with Zollinger-Ellison syndrome * Patients that investigators consider ineligible for this study